Skip to Content
  • Title
    CEO
  • Affiliation
    Mylan
  • Age
    46

Bresch has overseen a lot of drama at generic-drug maker Mylan in her nearly four years as CEO. After acquiring part of Abbott Laboratories earlier this year, Bresch moved the $7.7 billion Mylan to the Netherlands in a controversial “tax inversion” play, then thwarted a plan from Israel-based Teva to buy Mylan for $40 billion. Now Bresch is trying her own hostile takeover of Ireland-based Perrigo.

Read more about Heather Bresch in “Why Wall Street loves to hate Mylan’s CEO.”

41319CFF-E47E-4BA5-B1B8-ECA4D480B0DFCreated with sketchtool.62900797-6A09-46DF-8323-A45758A81292Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

Personal Information

Previous Rank31
Newcomer?
no

Company Financials

2014 Revenues
7,720
2014 Profits
929
Market Value (as of 9/1/15)
23,737